TPO and autoimmune thrombocytopenic purpura: As a full-length and glycosylated TPO developed by Shenyang Sunshine Pharmaceutical Co., Ltd., rhTPO was approved by the China State Food and Drug Administration as a second-line option for ITP (Zhou et al., 2015).